TAF9 Antikörper (AA 1-264)

Produktnummer ABIN7172703

Der Kaninchen Polyklonal Anti-TAF9-Antikörper wurde für WB, ELISA und IHC validiert. Er ist geeignet, TAF9 in Proben von Human zu detektieren.

Kurzübersicht für TAF9 Antikörper (AA 1-264) (ABIN7172703)

Target: TAF9 (RNA Polymerase II TBP-Associated Factor Subunit G (TAF9))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser TAF9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Produktdetails anti-TAF9 Antikörper

Bindungsspezifität: AA 1-264

Kreuzreaktivität: Human

Aufreinigung: Antigen Affinity Purified

Immunogen: Recombinant Human Transcription initiation factor TFIID subunit 9 protein (1-264AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:1000-1:5000, IHC:1:20-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu TAF9

Target: TAF9 (RNA Polymerase II TBP-Associated Factor Subunit G (TAF9))

Andere Bezeichnung: TAF9

Hintergrund:

Background: Component of TFIID, the TATA-binding protein-free TAF complex (TFTC), the PCAF complex and the STAGA transcription coactivator-HAT complex. The PCAF complex consists at least of TADA2L/ADA2, SUPT3H/SPT3, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65-alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. The STAGA transcription coactivator-HAT complex consists at least of SUPT3H, GCN5L2, SUPT7L, TAF5L, TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. Binds N-terminal domain of p53/TP53 which is essential for transcription. Component of some MLL1/MLL complex, at least composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the facultative components BAP18, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, MYST1/MOF, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Binds TFIIB and the Herpes simplex virus activator VP16. Forms a heterodimer with TAF6/TAFII80 in a complex with the TAF4B/TAFII105-TAF12/TAFII20 heterodimer. Also interacts with TAF5. Binds directly DNA. Increased DNA binding when complexed with TAF6/TAFII80.

Aliases: TAF9 antibody, TAF2G antibody, TAFII31 antibody, Transcription initiation factor TFIID subunit 9 antibody, RNA polymerase II TBP-associated factor subunit G antibody, STAF31/32 antibody, Transcription initiation factor TFIID 31 kDa subunit antibody, TAFII-31 antibody, TAFII31 antibody, Transcription initiation factor TFIID 32 kDa subunit antibody, TAFII-32 antibody, TAFII32 antibody

UniProt: Q16594

Pathways: Negative Regulation of intrinsic apoptotic Signaling